24 January 2022 | News
To explore opportunities for further collaboration and knowledge sharing
image credit- IVI
The International Vaccine Institute (IVI) in South Korea and the National Vaccine Institute (NVI) of Thailand have signed a Definitive Agreement to strengthen the collaborative partnership between the two organizations.
The agreement was signed by Dr. Jerome Kim, Director General of the IVI, and Dr. Nakorn Premsri, Director of NVI, witnessed by Dr. Manki Song, Deputy Director General of Science of IVI, and Dr. Sunate Cheunkitmongkol, Deputy Director of NVI.
This agreement will strengthen the collaborative relationship enjoyed by IVI and NVI since NVI’s establishment in 2018. IVI has been working on several vaccine R&D programs in Thailand since 2002, including an HPV single-dose study, a Pneumococcal Conjugate Vaccine (PCV) country investment case study, Dengue vaccine research and clinical trials, an Oral Cholera Vaccine (OCV) Phase II clinical trial, and studies on Shigella and Japanese Encephalitis (JE).
As of 2022, IVI is conducting several clinical trials in Thailand, including Phase II/III clinical trial of Chikungunya vaccine, SK bioscience COVID-19 vaccine trials, Johnson & Johnson COVID-19 vaccine clinical trial with Mahidol University. These programs have been conducted in collaboration with local partners in Thailand, including the Thai CDC, the Ministry of Public Health, and NVI.
From 2002 until 2019, over 70 Thai scientists and physicians have received training in IVI’s annual International Vaccinology Course held in Seoul, South Korea. In 2021, NVI supported IVI’s 20th International Vaccinology Course, which was held virtually, and 182 registrants were from Thailand.